Suggested in the sense that there was no chance for approval via in-house politics or suggested in the sense that we have found xyz and you may want to reconsider your application and further examine your compound. If it is the latter then again we as shareholders deserve to know the conversation in its entirety. I know the conference call explained the phone call but based on the FDA's response to "inactivation" it would appear more information would have been exchanged.
I am done with what could have, should have, been done by Stoll and will concentrate on the future, it just appears, again in my mind, that our chief knew he made a mistake and is unwilling to admit fault or reason.
Market Data 
Markets 
AI
